Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: sector stocks are volume centric and sensitive

December 28, 2018 5:58pm

Short sellers covered and are in the money this week as funds re-balance into equities but hedges lay-them-back-out (short positions) again anticipating year-end and Q4 results

Volatility is just a friends-with-benefits agreement while the clock ticks down on quarter’s and 2018’s end

Pre-open indications: 3 HITs

Out and about: HSGX (-$0.0031 to $0.09) – bankruptcy or shell sale; MDXG (-$0.05 to $1.50) – the FBI responded and deeper it dove - how far some Humpy Dumpties’ have fallen while ATHX (-$0.01) dives on its possible option on MultiStem; SLDB (-$0.21) dives on uncertainty and risk factors while BSTG (+$0.29) jumps on being all-but-broke with the desperate need of a financing. It’s the old story: when someone mentioned brains, they thought they said pains and said they don’t want any!

Investors should be reading about today’s final “figures” – be a subscriber and be ready for Monday’s … down bouncing session!

The 6 W’s: Who, what, where, when, why and what of it …

Daily analytics:

The Dow closed down -76.42 points or -0.33% to 23,062.40
The S&P closed down -3.09 points or -0.12% to 2,485.74
The NASDAQ was up +5.03 points or +0.08% to 6,584.52

Henry’omics:

The RegMed sector closed higher on Friday as markets concluded a roller-coaster week.

We're in the last-quarter and year-end periods where there are a lot of investors who have stepped away from the market and therefore some significant upsides in buying or sells have been made by traders!

The NASDAQ eked out a gain of 0.08% to end at 6,584.52, but closed well off its session high. Gains in ALNY, VCEL, ONCE and BLFS led the sector while the downsiders – IONS, BMRN, BLUE and SLDB stumbled.

For the week, the major averages all rose at least 2.75%, notching their first weekly gain in four. Stocks are still, however, on track for their worst December performance since 1931. The S&P 500 was down 9.9% for the month while the Dow has lost 9.7%.

From the pre-open newsletter: “the volatility tug-of-war as the year and quarter come closer to the end. Last night I stated, “So, I ask what NORMAL is these December days and are we closer to a bottom or a top (?) – I say bottom!”

The advance/decline line scenario of 45 covered companies:

The open was positive with an A/DL of 31/13 and 1 flat;
The mid-day was positive with an A/DL of 33/11 and 1 flat;
The close was positive with an A/DL of 31/12 and 2 flats;

Pre-open indications: 3 HITs

CRISPER Therapeutics (CRSP) closed UP +$0.34 – hit, I’d said trade it;
Editas medicine (EDIT) closed UP +$0.40 – hit, I’d said trade it;
Intellia (NTLA) closed UP +$0.72 – hit, I’d said trade it;

Daily sector metrics: rebalancing

… Greatest volume to the downside: HSGX, MDXG, BMRN, IONS and ATHX

… Upside volume was weighted to: VSTM, SGMO, XON, VCEL and NTLA

… Weakness ($) to the downside: IONS (-$1.76), BMRN (-$0.40), BLUE (-$0.34), SLDB (-$0.21) and RARE (-$0.15)

… Moves ($) to the upside: ALNY (+$1.81), VCEL (-$1.58), ONCE (+$1.53), BLFS (+$1.39) and QURE (+$1.12)

… The week’s history lesson, the iShares NASDAQ Biotechnology (IBB) closed:

Friday was down -0.34% after NOT indicating in the pre-market;
Thursday was up +0.03% after NOT indicating in the pre-market;
Wednesday was up +5.80% after indicating a POSITIVE +0.09% in the pre-market;
Tuesday was Christmas and closed;
Monday was down -1.38% after NOT indicating in the pre-market;
Last Friday was down -3.91% after NOT indicating in the pre-market;

Tonight’s percentage (%) indicators:

Review the range of the 31 upside from +0.33% (GBT) to +14.58% (KOOL +$0.035) while the 12 downside ranged from -0.34% (BLUE) to -3.87% (BLCM) with 2 flat close (BOLD and RENE.L)

Volume stat:

15 out of the 31 upside had higher (than the 3 month average) volume
4 out of the 12 downside experienced greater volume (than the 3 month average)

December sessions:

Friday closed POSITIVE with 12 decliners, 31 advancers and 2 flats;

Thursday closed NEGATIVE with 24 decliners, 20 advancers and 1 flat;

Wednesday closed POSITIVE with 7 decliners, 37 advancers and 1 flat;

Tuesday, the market was closed – Christmas;

Monday closed POSITIVE with 21 decliners, 23 advancers and 1 flat;

Friday closed NEGATIVE with 42 decliners, 3 advancers and 0 flat;

Thursday closed NEGATIVE with 36 decliners, 8 advancers and 1 flat;

Wednesday closed NEGATIVE with 34 decliners, 9 advancers and 2 flat;

Tuesday closed NEGATIVE with 36 decliners, 8 advancers and 1 flat;

Monday closed NEGATIVE with 34 decliners, 9 advancers and 2 flats;

Friday closed NEGATIVE with 30 decliners, 13 advancers and 2 flats;

Thursday closed NEGATIVE with 36 decliners, 8 advancers and 1 flat;

Wednesday closed POSITIVE with 8 decliners, 35 advancers and 2 flat;

Tuesday closed NEUTRAL with 21 decliners, 21 advancers and 3 flat;

Monday closed POSITIVE with 18 decliners, 25 advancers and 1 flat;

Friday closed NEGATIVE with 33 decliners, 11 advancers and 1 flat;

Thursday closed POSITIVE with 20 decliners, 22 advancers and 3 flats;

Wednesday markets were closed;

Tuesday closed NEGATIVE with 36 decliners, 7 advancers and 2 flats;

Monday (12/3) closed POSITIVE with 10 decliners, 32 advancers and 3 flats;

In 22 sessions in November – there were 1 holiday, 10 positive closes, 1 neutral and 10 negative closes;
In 23 sessions in October – there were 17 negative closes and 6 positive closes

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.